AT-014 Osteosarcoma Vaccine

Reprinted from American Veterinarian Article - January 5th, 2018


"Osteosarcoma is the most common primary bone tumor in dogs, but a new vaccine is striving to change that narrative. Aratana Therapeutics, a company focused on innovative therapeutics for dogs and cats, announced that their Canine Osteosarcoma Vaccine, Live Listeria Vector (AT-014), has been granted a conditional license by the United States Department of Agriculture (USDA) Center for Veterinary Biologics.

The vaccine uses a listeria-based antigen delivery system that activates cytotoxic T-cells. This directs the T-cells to fight off cancer cells—capitalizing on the dog’s immune system and its ability to attack bacterial infections.

"We know that most of these dogs relapse with metastatic disease, so clearly cancer is left after chemotherapy," said Nicola J. Mason, BVetMed, PhD, assistant professor of medicine and pathobiology at the University of Pennsylvania School of Veterinary Medicine and principal investigator of clinical trials investigating the new vaccine. "And we were asking the question: Could this vaccine induce an immune response which would eliminate those remaining cancer cells?”

During a clinical trial, researchers evaluated 18 dogs with primary tumor removal and gave them 4 doses of carboplatin chemotherapy followed by the new canine osteosarcoma vaccine every 3 weeks for 3 doses. The median survival rate was 956 days with the vaccine, compared with 423 days in a historical control group."



If you would like to learn more, please contact us at  425-697-2272 for more information.

Gold Nanoparticles

Nanoparticles treatment.jpg

We are conducting a trial for dogs with small mast cell tumors (<1.25cm) and oral squamous cell carcinoma in cats. This new clinical trial utilizes gold nanoparticles in a gross disease setting.

Gold Nanoparticles are inert and are given IV to the patient and after a period of time the patient comes back to have the tumor heated with a laser. As the tumor vasculature is heated through the external near infrared spectrum of light, the gold nanoparticles are excited, the laser energy is converted to heat and the tumor vasculature is disrupted killing the tumor from the inside out.


1. Small mast cell tumors of <1.25cm size in all dimensions - reduced cost of trial to client but multiple sites can be treated for the same cost.


If you have a potential case to discuss or have a patient with a small mast cell tumor in a bad location for surgery or if you would like to learn more,
please contact us at 425-697-2272 for more information.

Immunocidin for Hemangiosarcoma

Golden Retreiver.JPG

Now recruiting Dogs for a new Clinical Study for Hemangiosarcoma!

BARC is partnering with Iowa State University in conducting a clinical trial for dogs with Hemangiosarcoma. We will be assessing an immunotherapy (Immunocidin) paired in combination with Doxorubicin (traditional chemotherapy)

To be enrolled, dogs must have:

1. Confirmed Splenic hemangiosarcoma (histopathology)

2. Splenic Hemangiosarcoma Stage I or II and have undergone splenectomy

3. Have an ECOG performance score of 0 to 1

4. Remain off all other supplements during trial period (Yunnan Baiyao, mushroom extracts, other immunotherapy, steroids, etc)

Dogs can NOT have:

1. Received any steroids or other chemotherapy prior to enrollment

2. Concurrent malignancy other than hemangiosarcoma

3. Serious systemic disorder

Please contact us today for more information!

Imprimed logo.JPG

Personalized Chemotherapy with ImpriMed-V Assay for Canine Lymphoma

Now offering a way to get immunophenotype for lymphoma patients for precision medicine for patients.

BARC is partnering with Imprimed in conducting research on canine lymphoma cells. ImpriMed collects both gene and cell information directly from pets’ cancer cells. Their unique and extensive database will be translated into human oncology and also provide research insights into fighting human cancer.

By your lymphoma patient donating cells to this project, they will assess each patients cells for their sensitivity to specific chemotherapy drugs in an effort to get baseline information on personalized chemotherapy approaches. In return, they will run Flow cytometry and PARR to classify these cells and provide this information back to BARC at the cost of the aspirates to the client.

To receive the immunophenotyping:

1. Confirmed canine lymphoma

2. Sampling must be possible & performed with multiple aspirates of the organ involved (spleen, liver or LNs)

3. Can be naive patients or already treated resistant patients

Please contact us today for more information!